Administration of Subcutaneous IL-2 is Associated with Strong Induction of Regulatory T Cells in High-Risk Neuroblastoma Patients Treated with Dinutuximab Beta, A SIOPEN Study

PEDIATRIC BLOOD & CANCER(2019)

引用 1|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要